Although our experimental findings suggest that the dual inhibition of KIF11 plus BCL2L1 is effective against classic (neuroendocrine) SCLC, namely SCLC-A and SCLC-N subtypes, we extensively analyzed only two SCLC cell lines in vitro. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.